Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Long-Term Debt Issuances (2022)

UroGen Pharma's Long-Term Debt Issuances history spans 1 years, with the latest figure at $25.0 million for Q4 2022.

  • For Q4 2022, Long-Term Debt Issuances changed N/A year-over-year to $25.0 million; the TTM value through Sep 2023 reached $25.0 million, down 64.7%, while the annual FY2024 figure was $24.5 million, N/A changed from the prior year.
  • Long-Term Debt Issuances reached $25.0 million in Q4 2022 per URGN's latest filing, up from -$38000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $70.8 million in Q1 2022 to a low of -$38000.0 in Q2 2022.